Altered gene expression in the prefrontal cortex of young rats induced by the ADHD drug atomoxetine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 40, Issue 1, 2013, Pages 221-228

  Lempp, Thomas ^a   Toennes, Stefan W ^a   Wunder, Cora ^a   Russe, Otto Quintus ^a   Möser, Christine V ^a   Kynast, Katharina L ^a   Freitag, Christine M ^a   Niederberger, Ellen ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Child psychiatry; Gene expression; Synaptosomal associated protein of 25kDa

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; ATOMOXETINE; GENOMIC RNA; MEMBRANE PROTEIN; MESSENGER RNA; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; VESICLE PROTEIN;

ADOLESCENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILDHOOD; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DOWN REGULATION; DRUG BLOOD LEVEL; GENE EXPRESSION; GENE FUNCTION; LONG TERM CARE; MALE; MICROARRAY ANALYSIS; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREFRONTAL CORTEX; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; UNINDEXED SEQUENCE; UPREGULATION; WESTERN BLOTTING;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; ELECTRON TRANSPORT COMPLEX III; GENE EXPRESSION; MALE; PREFRONTAL CORTEX; PROPYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TISSUE ARRAY ANALYSIS;

EID: 84868257163     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.08.012     Document Type: Article

References (52)

1. Adriani W., Leo D., Greco D., Rea M., di Porzio U., Laviola G., et al. Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression. Neuropsychopharmacology 2006, 31:1946-1956.
2. Andersen S.L. Stimulants and the developing brain. Trends Pharmacol Sci 2005, 26:237-243.
3. Biederman J., Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 2005, 366:237-248.
4. Brophy K., Hawi Z., Kirley A., Fitzgerald M., Gill M. Synaptosomal-associated protein 25 (SNAP-25) and attention deficit hyperactivity disorder (ADHD): evidence of linkage and association in the Irish population. Mol Psychiatry 2002, 7:913-917.
5. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
6. Casey B.J., Epstein J.N., Buhle J., Liston C., Davidson M.C., Tonev S.T., et al. Frontostriatal connectivity and its role in cognitive control in parent-child dyads with ADHD. Am J Psychiatry 2007, 164:1729-1736.
7. Chase T., Carrey N., Soo E., Wilkinson M. Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Neuroscience 2007, 144:969-984.
8. Choi T.K., Lee H.S., Kim J.W., Park T.W., Song D.H., Yook K.W., et al. Support for the MnlI polymorphism of SNAP25; a Korean ADHD case-control study. Mol Psychiatry 2007, 12:224-226.
9. Corradini I., Verderio C., Sala M., Wilson M.C., Matteoli M. SNAP-25 in neuropsychiatric disorders. Ann N Y Acad Sci 2009, 1152:93-99.
10. Dell'Agnello G., Zuddas A., Masi G., Curatolo P., Besana D., Rossi A. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 2009, 23:739-753.
11. DeLorey T.M., Handforth A., Anagnostaras S.G., Homanics G.E., Minassian B.A., Asatourian A., et al. Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. J Neurosci 1998, 18:8505-8514.
12. Elia J., Glessner J.T., Wang K., Takahashi N., Shtir C.J., Hadley D., et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet 2011, 44:78-84.
13. Fagundes A.O., Aguiar M.R., Aguiar C.S., Scaini G., Sachet M.U., Bernhardt N.M., et al. Effect of acute and chronic administration of methylphenidate on mitochondrial respiratory chain in the brain of young rats. Neurochem Res 2010, 35:1675-1680.
14. Fagundes A.O., Scaini G., Santos P.M., Sachet M.U., Bernhardt N.M., Rezin G.T., et al. Inhibition of mitochondrial respiratory chain in the brain of adult rats after acute and chronic administration of methylphenidate. Neurochem Res 2010, 35:405-411.
15. Faraone S.V., Perlis R.H., Doyle A.E., Smoller J.W., Goralnick J.J., Holmgren M.A., et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57:1313-1323.
16. Feng Y., Crosbie J., Wigg K., Pathare T., Ickowicz A., Schachar R., et al. The SNAP25 gene as a susceptibility gene contributing to attention-deficit hyperactivity disorder. Mol Psychiatry 2005, 10:998-1005.
17. Fumagalli F., Cattaneo A., Caffino L., Ibba M., Racagni G., Carboni E., et al. Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate. Pharmacol Res 2010, 62:523-529.
18. Garnock-Jones K.P., Keating G.M. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs 2010, 24:85-88.
19. Gau S.S., Huang Y.S., Soong W.T., Chou M.C., Chou W.J., Shang C.Y., et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007, 17:447-460.
20. Gizer I.R., Ficks C., Waldman I.D. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009, 126:51-90.
21. Hess E.J., Collins K.A., Wilson M.C. Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. J Neurosci 1996, 16:3104-3111.
22. Hess E.J., Jinnah H.A., Kozak C.A., Wilson M.C. Spontaneous locomotor hyperactivity in a mouse mutant with a deletion including the Snap gene on chromosome 2. J Neurosci 1992, 12:2865-2874.
23. Homanics G.E., DeLorey T.M., Firestone L.L., Quinlan J.J., Handforth A., Harrison N.L., et al. Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior. Proc Natl Acad Sci U S A 1997, 94:4143-4148.
24. Iwamoto K., Bundo M., Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005, 14:241-253.
25. Kaplan G., Newcorn J.H. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am 2011, 58:99-120.
26. Kelsey D.K., Sumner C.R., Casat C.D., Coury D.L., Quintana H., Saylor K.E., et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004, 114:e1-e8.
27. Kobayashi T., Washiyama K., Ikeda K. Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine. Neuropsychopharmacology 2010, 35:1560-1569.
28. Koda K., Ago Y., Cong Y., Kita Y., Takuma K., Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 2010, 114:259-270.
29. Li C.S., Zhang L., Haske T., Dounay A., Gray D., Barta N., et al. Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist. AAPS J 2012, 14:365-376.
30. Li Q., Wong J.H., Lu G., Antonio G.E., Yeung D.K., Ng T.B., et al. Gene expression of synaptosomal-associated protein 25 (SNAP-25) in the prefrontal cortex of the spontaneously hypertensive rat (SHR). Biochim Biophys Acta 2009, 1792:766-776.
31. Ludolph A.G., Udvardi P.T., Schaz U., Henes C., Adolph O., Weigt H.U., et al. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol 2010, 160:283-291.
32. Masuo Y., Ishido M., Morita M., Sawa H., Nagashima K., Niki E. Behavioural characteristics and gene expression in the hyperactive wiggling (Wig) rat. Eur J Neurosci 2007, 25:3659-3666.
33. Mattiuz E.L., Ponsler G.D., Barbuch R.J., Wood P.G., Mullen J.H., Shugert R.L., et al. Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. Drug Metab Dispos 2003, 31:88-97.
34. Neale B.M., Medland S., Ripke S., Anney R.J., Asherson P., Buitelaar J., et al. Case-control genome-wide association study of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010, 49:906-920.
35. Newcorn J.H., Kratochvil C.J., Allen A.J., Casat C.D., Ruff D.D., Moore R.J., et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008, 165:721-730.
36. Perwien A.R., Faries D.E., Kratochvil C.J., Sumner C.R., Kelsey D.K., Allen A.J. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr 2004, 25:264-271.
37. Pouget P., Wattiez N., Rivaud-Pechoux S., Gaymard B. A fragile balance: perturbation of GABA mediated circuit in prefrontal cortex generates high intraindividual performance variability. PLoS One 2009, 4:e5208.
38. Pozzi D., Condliffe S., Bozzi Y., Chikhladze M., Grumelli C., Proux-Gillardeaux V., et al. Activity-dependent phosphorylation of Ser187 is required for SNAP-25-negative modulation of neuronal voltage-gated calcium channels. Proc Natl Acad Sci U S A 2008, 105:323-328.
39. Pringsheim T., Steeves T. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011, CD007990.
40. Renner T.J., Walitza S., Dempfle A., Eckert L., Romanos M., Gerlach M., et al. Allelic variants of SNAP25 in a family-based sample of ADHD. J Neural Transm 2008, 115:317-321.
41. Russell V.A. Overview of animal models of attention deficit hyperactivity disorder (ADHD). Curr Protoc Neurosci 2011, 54:9.35.1-9.35.25. [Chapter 9:Unit 9 35].
42. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000, 80:717-766.
43. Sontag T.A., Tucha O., Walitza S., Lange K.W. Animal models of attention deficit/hyperactivity disorder (ADHD): a critical review. Atten Defic Hyperact Disord 2010, 2:1-20.
44. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000, 24:417-463.
45. Sun H., Cocker P.J., Zeeb F.D., Winstanley C.A. Chronic atomoxetine treatment during adolescence decreases impulsive choice, but not impulsive action, in adult rats and alters markers of synaptic plasticity in the orbitofrontal cortex. Psychopharmacology (Berl) 2012, 219:285-301.
46. Sun X., Wang J.F., Tseng M., Young L.T. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci 2006, 31:189-196.
47. Swanson C.J., Perry K.W., Koch-Krueger S., Katner J., Svensson K.A., Bymaster F.P. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006, 50:755-760.
48. Uusi-Oukari M., Korpi E.R. Regulation of GABA(A) receptor subunit expression by pharmacological agents. Pharmacol Rev 2010, 62:97-135.
49. Verderio C., Pozzi D., Pravettoni E., Inverardi F., Schenk U., Coco S., et al. SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron 2004, 41:599-610.
50. Washbourne P., Thompson P.M., Carta M., Costa E.T., Mathews J.R., Lopez-Bendito G., et al. Genetic ablation of the t-SNARE SNAP-25 distinguishes mechanisms of neuroexocytosis. Nat Neurosci 2002, 5:19-26.
51. Weiss M., Tannock R., Kratochvil C., Dunn D., Velez-Borras J., Thomason C., et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005, 44:647-655.
52. Witcher J.W., Long A., Smith B., Sauer J.M., Heilgenstein J., Wilens T., et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003, 13:53-63.